Vaxart reported total revenue of $27.2 million for the quarter ended June 30, 2026, and a net loss of $13.5 million, with cash, cash equivalents, and short-term investments of $64.0 million.
Vaxart CEO Steve Lo and the BOD's need to put their "Boy Pants" and get the ball rolling faster and get their VAAST Oral Pill Vaccines for Corvid-19, Norovirus, Flu, RSV, etc approved by FDA and get it Commercialized so many lives can be saved ASAP..! Where is RFK? He should be pushing for Vaxart’s platform to get approved ASAP.
5
TahoeandChief
decreased liquidity? More like decreased dilution. Which to the already beaten down SHs is a good thing. Make them work for actual deals and not just free money on the backs of naive and optimistic retail.
5
Gordon99
still not bad funding of trial considering the enrollment number was cut in half but the funding was not
3
Edge
SackLo
Wrong - not bearish
The 2024 ATI-RRPV Contract total authorized funding was reduced from $460.7 million to $344.8 million, reflecting a reduction in scope of work and enrollment resulting from stop work orders
Trial size reduced by 50%, hence per capita increased significantly.
Bullish